文献速递介入腹部USMRCT

采用双冷湿电极的无接触射频消融治疗局部区域治疗后复发性肝细胞癌

No-Touch Radiofrequency Ablation Using Twin Cooled Wet Electrodes for Recurrent Hepatocellular Carcinoma Following Locoregional Treatments.
PubMed 文献 · Korean J Radiol · 2024-01-01

前瞻性单臂研究纳入102例患者共112个复发性肝细胞癌(每个≤3 cm),在超声-MR/CT融合成像引导下行双冷湿电极无接触射频消融,24个(21.4%)肿瘤需转为常规穿刺射频消融,111个(99.1%)治疗成功,无重大并发症;意向治疗分析2年及3年局部肿瘤进展累积发生率为6.0%,符合方案分析为1.3%。

要点

  • 无接触射频消融使用双冷湿电极治疗复发性肝细胞癌,112个肿瘤中24个(21.4%)需转为常规穿刺射频消融。
  • 意向治疗分析局部肿瘤进展累积发生率1年1.9%、2年6.0%、3年6.0%,符合方案分析1年0.0%、2年1.3%、3年1.3%。
  • 既往局部区域治疗次数、总胆红素及安全边缘≤5 mm与局部肿瘤进展独立相关。

核心结论

  • 采用双冷湿电极的无接触射频消融是治疗复发性肝细胞癌安全有效的方法,意向治疗分析2年和3年随访局部肿瘤进展累积发生率分别为6.0%和1.3%(符合方案分析)。

研究设计与样本

  • 前瞻性单臂研究,纳入102例患者共112个复发性肝细胞癌(每个≤3 cm),在超声-MR/CT融合成像引导下行双冷湿电极无接触射频消融,技术困难时允许转为常规肿瘤穿刺射频消融,主要指标为射频消融后局部肿瘤进展的中期累积发生率。

诊断标准与关键数值

  • 意向治疗分析(含所有患者)局部肿瘤进展累积发生率1年1.9%、2年6.0%、3年6.0%;符合方案分析(仅含无需转为常规射频消融的患者)1年0.0%、2年1.3%、3年1.3%;局部肿瘤进展独立相关因素:既往局部区域治疗次数(校正风险比1.265/每增加1次治疗,P=0.004)、总胆红素(校正风险比7.477/每增加1 mg/dL,P=0.012)、安全边缘≤5 mm(校正风险比9.029,P=0.016)。

临床应用与阅片要点

  • 无接触射频消融使用双冷湿电极可在超声-MR/CT融合成像引导下实施,技术困难时可转为常规肿瘤穿刺射频消融;安全边缘≤5 mm、既往局部区域治疗次数多及总胆红素升高与局部肿瘤进展风险独立相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the therapeutic outcomes of no-touch radiofrequency ablation (NT-RFA) using twin cooled wet (TCW) electrodes in patients experiencing recurrent hepatocellular carcinoma (HCC) after undergoing locoregional treatments.

MATERIALS AND METHODS: We conducted a prospective, single-arm study of NT-RFA involving 102 patients, with a total of 112 recurrent HCCs (each ≤ 3 cm). NT-RFA with TCW electrodes was implemented under the guidance of ultrasonography (US)-MR/CT fusion imaging. If NT-RFA application proved technically challenging, conversion to conventional tumor puncture RFA was permitted. The primary metric for evaluation was the mid-term cumulative incidence of local tumor progression (LTP) observed post-RFA. Cumulative LTP rates were estimated using the Kaplan-Meier method. Multivariable Cox proportional hazard regression was used to explore factors associated with LTP. Considering conversion cases from NT-RFA to conventional RFA, intention-to-treat (ITT; including all patients) and per-protocol (PP; including patients not requiring conversion to conventional RFA alone) analyses were performed.

RESULTS: Conversion from NT-RFA to conventional RFA was necessary for 24 (21.4%) out of 112 tumors. Successful treatment was noted in 111 (99.1%) out of them. No major complications were reported among the patients. According to ITT analysis, the estimated cumulative incidences of LTP were 1.9%, 6.0%, and 6.0% at 1, 2, and 3 years post-RFA, respectively. In PP analysis, the cumulative incidence of LTP was 0.0%, 1.3%, and 1.3% at 1, 2, and 3 years, respectively. The number of previous locoregional HCC treatments (adjusted hazard ratio [aHR], 1.265 per 1 treatment increase; P = 0.004), total bilirubin (aHR, 7.477 per 1 mg/dL increase; P = 0.012), and safety margin ≤ 5 mm (aHR, 9.029; P = 0.016) were independently associated with LTP in ITT analysis.

CONCLUSION: NT-RFA using TCW electrodes is a safe and effective treatment for recurrent HCC, with 6.0% (ITT analysis) and 1.3% (PP analysis) cumulative incidence of LTP at 2 and 3-year follow-ups.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Hong SJ, Kim JH, Yoon JH, et al. No-Touch Radiofrequency Ablation Using Twin Cooled Wet Electrodes for Recurrent Hepatocellular Carcinoma Following Locoregional Treatments. Korean J Radiol. 2024. PMID: 38685734. doi:10.3348/kjr.2023.1225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。